Shutdown Notice: Unfortunately I have shut down the Earnings Calls app and website. My data provider shut down their service and I couldn't find a viable alternative. If you purchased the iPhone app and feel like you didn't get your money's worth, please request a refund via the App Store. As a replacement, many brokerage services are adding earnings calls to their apps (like Robinhood, for example) or try Earningscast. Thank you to everyone who supported and enjoyed Earnings Calls, I'm sorry to let you down. – Justin Thiele

REGENXBIO Inc., a biotechnology company, focuses on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy. The company’s development programs include RGX-501, a product candidate for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111, a product candidate for the treatment of Mucopolysaccharidosis Type I, which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system (CNS). Its programs also include RGX-121, a product candidate for the treatment of Mucopolysaccharidosis Type II that uses the AAV9 vector to deliver the human iduronate-2-sulfatase gene to the CNS; RGX-314, a product candidate for the treatment of wet age-related macular degeneration; and RGX-321, a product candidate for the treatment of X-linked retinitis pigmentosa. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Read More

RGNX Conference Calls / Webcasts:

Date Time (Eastern) Title
  3/07/17 4:30 pm Regenxbio Inc Earnings (Q4 2016)
  8/09/16 8:30 am Regenxbio Inc Earnings (Q2 2016)
Appstore
StockTwits